Aunan Greg D sold $321K of NEO

Aunan Greg D (Chief Accounting Officer) sold 20,000 shares of NEOGENOMICS INC (NEO) at $16.07 ($0.32M total) on 2026-08-04.

Original reporting
SEC EDGAR · Aunan Greg D
Published Aug 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NEO
Neutral
low confidence
Mentioned
$NEO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NEONeutralLow
01

Why it matters

A single officer open-market sale can modestly affect sentiment, but it is not a fundamental datapoint like earnings, guidance, or a deal.

02

Market read

Traders may note the insider sale for sentiment, but there is no additional company-specific catalyst in the text.

03

What to watch

The filing does not include motives, and the post-sale holdings (5,153 shares) suggest the sale may be part of routine personal liquidity rather than a large conviction shift.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-06 for a sale dated 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for NEOGENOMICS.

Company-level read

Ticker impact

$NEONeutralLow confidence
Context

NEOGENOMICS insider Aunan Greg D sold 20,000 shares at $16.07 on 2026-08-04, per a newly filed Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

Form 4 provides transaction details but no accompanying company-specific catalyst, guidance change, or regulatory/legal event.

Market effects

No clear sector read-through from a single insider sale.

None.

None.

Counterpoint

Insider sales are often planned for diversification or tax needs; the absence of a stated 10b5-1 plan does not automatically imply negative information.

Key entities

  • NEOGENOMICS INC

    Subject of the Form 4 insider transaction disclosure.

  • Aunan Greg D

    Chief Accounting Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NEOMed

NeoGenomics Inc (NEO) Q3 2026 Earnings Call Highlights: Revenue Tops $209 Million as NGS

NeoGenomics Inc (NEO) reported Q3 2026 revenue of $209M, driven by 11% AUP growth from NGS products and RCM initiatives. CEO Tony Zook announced a transition to Warren Stone, emphasizing strategic alignment. The company expects continued AUP growth and slight pharma segment recovery in 2027, despite potential Medicare rate cuts. NGS volume growth is attributed to new products and sales force expansion.

$NEOHighAI 8/10

What NeoGenomics (NEO) Said on Its Q3 Earnings Call

NeoGenomics (NEO) reported Q3 earnings, raising 2026 revenue guidance to $807M-$809M and adjusted EBITDA to ~$60M. Cash decreased to $139M due to settlements and investments. The company plans a transition to the NovaSeq X platform, expecting financial benefits in 2027-2028. CEO transition announced for January 2027.

$NEOMedAI 8/10

NeoGenomics (NEO) Q3 2026 Earnings Call Transcript

NeoGenomics (NEO) reported Q3 2026 earnings with clinical revenue up 13% YoY, NGS revenue up 29%, and adjusted gross margins expanding by 300 basis points. Total revenue reached $209M, up 11% YoY. The company raised its full-year revenue and adjusted EBITDA guidance. CEO Tony Zook will step down, with Warren Stone taking over in January 2027.